SCHEDULE: Konar Family, Regolith Capital Boost Ernexa Therapeutics Stake

Shameek Konar, Victoria Konar, and Regolith Capital Investments LP collectively report beneficial ownership of 7.12% of Ernexa Therapeutics Inc. common stock.

Summary

• Shameek Konar, Victoria Konar, and Regolith Capital Investments LP (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
• The filing reports beneficial ownership of Ernexa Therapeutics Inc. (formerly Eterna Therapeutics Inc.) common stock.
• Shameek Konar and Victoria Konar each beneficially own 558,531 shares, representing 7.12% of the class.
• Regolith Capital Investments LP beneficially owns 547,668 shares, representing 6.98% of the class.
• The ownership percentage is based on 7,848,889 shares of Common Stock outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 7, 2025.
• Shameek Konar and Victoria Konar are the general partners of Regolith Capital Investments LP and share voting and dispositive power over Regolith's holdings.
• Shameek Konar directly owns 10,863 shares, which are included in his and Victoria Konar's aggregate beneficial ownership.
• The securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. A significant stake by an investment entity and its principals can be seen as a vote of confidence, but the filing itself is purely informational and not indicative of operational performance.

Positives

• Increased transparency regarding significant shareholder holdings.
• Continued investment by key individuals and an investment entity, potentially signaling confidence in the company.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future outlook.

Industry Context

This Schedule 13G filing indicates a significant passive investment in Ernexa Therapeutics Inc. by an investment partnership and its general partners. Such filings are common in the biotechnology and pharmaceutical sectors, where institutional and individual investors often take substantial positions in companies with promising therapeutic pipelines, signaling long-term interest without seeking active control. The specific impact on broader industry trends is limited as this is an ownership disclosure rather than an operational update.

Comparison to Industry Standards

• This filing is a standard Schedule 13G disclosure, which is a regulatory requirement for reporting beneficial ownership exceeding 5% of a company's outstanding shares.
• It aligns with industry standards for transparency in significant shareholder positions.
• No specific comparable companies, projects, or results are relevant for this type of filing, as it focuses solely on ownership percentages rather than operational or financial performance.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership, potentially signaling investor confidence.
• Management: Awareness of a substantial passive shareholder group.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of beneficial ownership and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The reporting persons explicitly state the securities were not acquired for the purpose of changing or influencing control. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to buy or sell based on new fundamental insights.

Keywords

Ernexa Therapeutics, Eterna Therapeutics, Regolith Capital Investments, Shameek Konar, Victoria Konar, beneficial ownership, Schedule 13G, common stock, institutional ownership, biotechnology